ResApp Health - First major clinical study of ResAppDx reports important data

Stuart Roberts

Pitt Street Research and NDF Research

In July 2016 NDF research initiated coverage on ResApp Health, a company developing a smartphone-based diagnostic for respiratory disease. ResApp has just reported important data from the first major clinical study of the ResAppDx, a smartphone-based diagnostic for respiratory disease which we have previously called the ResApp System. This Australian study in pediatric patients was not a study for registration purposes but has shown that the ResAppDx works very well as a diagnostic across a broad range of childhood respiratory diseases (including upper respiratory tract infection, croup, bronchiolitis, pneumonia and asthma), each of which provides a clinically-valuable diagnosis. ResApp’s US study in pediatric patients, which is being conducted to gain FDA approval, has now completed recruitment and ResApp’s investigators will now evaluate the data using the algorithms perfected during the Australian Pediatric Study. Should the US Pediatric Study be successful, we expect a filing shortly for De Novo approval in the second half of 2017, with approval expected in late 2017 or early 2018.

You can download a copy of NDF Research's update report on ResApp Health by clicking here. I commend the update report to you.

ResApp 12-month chart

1 stock mentioned

Stuart Roberts
Founder and Senior Analyst
Pitt Street Research and NDF Research

I am an equity research professional who worked in stockbroking from 2001 to 2015. After 15 months doing investor relations I returned to equity research with the founding of NDF Research. With Marc Kennis I founded Pitt Street Research in July 2018.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.